Skip to main content

Enanta Pharmaceuticals Inc

ENTA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001177648

No open-market purchases or sales by Enanta Pharmaceuticals Inc insiders were filed in the last 90 days; 122 institutions reported holding it in 13F filings for Q2 2026, worth $397.2M in total; no superinvestor holds it.

Q2 2025 vs. Q1 2025

How the institutions holding Enanta Pharmaceuticals Inc changed between Q1 2025 and Q2 2025.

All holders in Q2 2025All holders in Q1 2025

13F holders of ENTA: Q1 2025 compared with Q2 2025
MeasureQ1 2025Q2 2025Change
Holders110108−2
Shares18.6M18.4M−183.0K (−1.0%)
Value$102.8M$139.4M+$36.6M (+35.6%)

New holders (15)

Institutions that held Enanta Pharmaceuticals Inc at the end of Q2 2025 but not at the end of Q1 2025.

Institutions new to ENTA in Q2 2025
InstitutionSharesValue% of portfolio
Janus Henderson Group PLC523,743$3.96M0.00%
Skopos Labs, Inc.42,514$321.4K0.04%
Virtu Financial LLC31,533$238.0K0.01%
Sanctuary Advisors, LLC25,427$192.2K0.00%
Wealth Enhancement Advisory Services, LLC11,111$87.7K0.00%
Essential Partners LLC1,573$11.9K0.00%
Versant Capital Management, Inc1,424$10.8K0.00%
IFP Advisors, Inc385$3.08K0.00%
Simplex Trading, LLC350$2.00K0.00%
Allworth Financial LP228$1.72K0.00%
Parkside Financial Bank & Trust71$8970.00%
Fifth Third Bancorp111$8390.00%
Group One Trading, L.P.100$7560.00%
Raymond James Financial Inc50$3780.00%
Clearstead Advisors, LLC9$690.00%

Sold out (17)

Institutions that held Enanta Pharmaceuticals Inc at the end of Q1 2025 and filed for Q2 2025 without it.